Navigation Links
Combined drug therapy to treat TB and HIV significantly improves survival
Date:2/25/2010

Initiating antiretroviral therapy (ART) during tuberculosis therapy significantly reduced mortality rates by 56 percent in a randomized clinical trial of 642 patients co-infected with HIV and tuberculosis. The study, which provides further impetus for the integration of TB and HIV services, lays to rest the controversy on whether co-infected patients should initiate ART during or after TB treatment. Findings are published in the February 25th issue of The New England Journal of Medicine.

Tuberculosis is the most common opportunistic disease and the most frequent cause of death in patients with HIV infection in developing countries, and the number of patients with co-infection continues to grow rapidly.

"Despite World Health Organization(WHO) guidelines supporting concomitant treatment of the two diseases and urging more aggressive management initiation of antiretroviral therapy, treatment often has been deferred until completion of tuberculosis therapy because of concern about potential drug interactions, overlapping side effects, a high pill burden, and programmatic challenges," said Salim S. Abdool Karim, MD, PhD, professor of clinical epidemiology at Columbia University's Mailman School of Public Health, pro vice-chancellor (research) at the University of KwaZulu-Natal in Durban, South Africa, and principal investigator of the study.

The new study, called the Starting Antiretroviral Therapy at Three Points in Tuberculosis (SAPiT), was designed to determine the optimal time to initiate antiretroviral therapy in patients with HIV and tuberculosis co-infection who were receiving tuberculosis therapy. The trial was conducted at the eThekwini HIVtuberculosis clinic, operated by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) in Durban, South Africa.

Of the 642 patients in the trial, 429 were in the combined integrated-therapy groups who initiated ART during TB treatment as compared with the 213 patients in the sequential-therapy group who initiated ART only after TB treatment was completed. Only patients with TB and HIV infection with a CD4+ cell count of less than 500 cells per cubic millimeter were included in the study.

All patients received standard tuberculosis therapy and a once-daily antiretroviral regimen.

Based on the results of this study, the World Health Organization guidelines for treatment of TB and HIV co-infection were revised in late 2009. On World AIDS Day in 2009, President Zuma of South Africa announced the new policy, to provide ART to all TB patients with HIV infection and CD4 counts below 350 cells per cubic millimeter.

"Our findings provide compelling evidence of the benefit of initiating antiretroviral therapy during tuberculosis therapy in patients with HIV co-infection, and also support recommendations by the WHO and others for the integration of tuberculosis and HIV care," notes Dr. Karim.


'/>"/>

Contact: Stephanie Berger
sb2247@columbia.edu
212-305-4372
Columbia University's Mailman School of Public Health
Source:Eurekalert

Related medicine news :

1. Combined mammography and breast MRI useful for some high-risk women
2. Green tea chemical combined with another may hold promise for treatment of brain disorders
3. Holistic and Western Medicine Combined Can Fight Cancer
4. UnitedHealthcare To Offer Seniors Hispanic-Centered Medicare Education Seminars Combined With a Latin-Themed Fitness Program
5. Report Finds Alzheimer's Killing More People Than Breast And Prostate Cancer Combined
6. Research: People With Type 2 Diabetes Improved Muscular Strength and Exercise Capacity Through Physical Therapist Exercise Counseling Combined With Fitness Center Exercise Training
7. Study finds promise in combined transplant/vaccine therapy for high-risk leukemia
8. FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia
9. Recently Released Data from the National Survey of Childrens Health Reports That Autism Now Affects 1% of Children and is More Common Than Childrens Cancer, Diabetes, and AIDS Combined.
10. Hard To Treat Diseases (HTDS) Clinical Trial Update on Therapeutic effects of Combined Treatment With Ribavirin And Tiazofurin
11. Childrens Hospital of Philadelphia Earns Highest Combined US News Score in 10 Specialties Ranked by U.S. News & World Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Beach to host its Swirl: Miami Wine Tasting Event on March 28, 2017. ...
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... Los ... two episodes of WE TV’s “Mama June: From Not to Hot,” which will begin ... notable, “Mama” June Shannon, known to millions from the 2012 reality television series, “Here ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... content provider for the National Institute for Health and Care Excellence ... organizations in the National Health Service (NHS) to search, order and purchase medical ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... exciting, new, interactive publication where generations converge and explore the world from different ... worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and find greater ...
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare Research & ... in the fight against cancer, has produced a seminal study that asked cancer ... release top-line findings in a webinar, Defining Compassionate Care Through the Voices of ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017  Genesis Healthcare Services has merged with Hospice ... by Bill Monast , President and CEO of ... Nathan Feltman , executives with Home Health Depot, Inc., ... This acquisition helps Hospice Cloud maintain its ... durable medical equipment (DME) solutions for the hospice industry. ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... offering. ... Menopause Drugs Price Analysis and Strategies - 2016, provides drug pricing data ... following questions: What are the key drugs ... the Global Menopause market? What are the unit prices ...
(Date:2/23/2017)... , Feb. 23, 2017 Regulus ... the discovery and development of innovative medicines targeting microRNAs, ... year 2016 financial results on Thursday, March 2, 2017 ... a conference call and webcast on March 2, 2017 ... and full year 2016 financial results and provide a ...
Breaking Medicine Technology: